254 related articles for article (PubMed ID: 29235481)
1. Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia.
Jiang X; Hu C; Ferchen K; Nie J; Cui X; Chen CH; Cheng L; Zuo Z; Seibel W; He C; Tang Y; Skibbe JR; Wunderlich M; Reinhold WC; Dong L; Shen C; Arnovitz S; Ulrich B; Lu J; Weng H; Su R; Huang H; Wang Y; Li C; Qin X; Mulloy JC; Zheng Y; Diao J; Jin J; Li C; Liu PP; He C; Chen Y; Chen J
Nat Commun; 2017 Dec; 8(1):2099. PubMed ID: 29235481
[TBL] [Abstract][Full Text] [Related]
2. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
Huang H; Jiang X; Wang J; Li Y; Song CX; Chen P; Li S; Gurbuxani S; Arnovitz S; Wang Y; Weng H; Neilly MB; He C; Li Z; Chen J
Cancer Lett; 2016 Mar; 372(2):157-65. PubMed ID: 26791235
[TBL] [Abstract][Full Text] [Related]
3. High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia From Two Cohorts.
Wang J; Li F; Ma Z; Yu M; Guo Q; Huang J; Yu W; Wang Y; Jin J
EBioMedicine; 2018 Feb; 28():90-96. PubMed ID: 29402726
[TBL] [Abstract][Full Text] [Related]
4. TET1 plays an essential oncogenic role in MLL-rearranged leukemia.
Huang H; Jiang X; Li Z; Li Y; Song CX; He C; Sun M; Chen P; Gurbuxani S; Wang J; Hong GM; Elkahloun AG; Arnovitz S; Wang J; Szulwach K; Lin L; Street C; Wunderlich M; Dawlaty M; Neilly MB; Jaenisch R; Yang FC; Mulloy JC; Jin P; Liu PP; Rowley JD; Xu M; He C; Chen J
Proc Natl Acad Sci U S A; 2013 Jul; 110(29):11994-9. PubMed ID: 23818607
[TBL] [Abstract][Full Text] [Related]
5. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
[TBL] [Abstract][Full Text] [Related]
6. Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC.
Li C; Dong L; Su R; Bi Y; Qing Y; Deng X; Zhou Y; Hu C; Yu M; Huang H; Jiang X; Li X; He X; Zou D; Shen C; Han L; Sun M; Skibbe J; Ferchen K; Qin X; Weng H; Huang H; Song C; Chen J; Jin J
Haematologica; 2020 Jan; 105(1):148-160. PubMed ID: 30975912
[TBL] [Abstract][Full Text] [Related]
7. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.
Cook AM; Li L; Ho Y; Lin A; Li L; Stein A; Forman S; Perrotti D; Jove R; Bhatia R
Blood; 2014 May; 123(18):2826-37. PubMed ID: 24668492
[TBL] [Abstract][Full Text] [Related]
8. MYC deregulates TET1 and TET2 expression to control global DNA (hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL.
Poole CJ; Lodh A; Choi JH; van Riggelen J
Epigenetics Chromatin; 2019 Jul; 12(1):41. PubMed ID: 31266538
[TBL] [Abstract][Full Text] [Related]
9. Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia.
Seipel K; Graber C; Flückiger L; Bacher U; Pabst T
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360855
[TBL] [Abstract][Full Text] [Related]
10. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
[TBL] [Abstract][Full Text] [Related]
11. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
12. TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition.
Bamezai S; Demir D; Pulikkottil AJ; Ciccarone F; Fischbein E; Sinha A; Borga C; Te Kronnie G; Meyer LH; Mohr F; Götze M; Caiafa P; Debatin KM; Döhner K; Döhner H; González-Menéndez I; Quintanilla-Fend L; Herold T; Jeremias I; Feuring-Buske M; Buske C; Rawat VPS
Leukemia; 2021 Feb; 35(2):389-403. PubMed ID: 32409690
[TBL] [Abstract][Full Text] [Related]
13. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.
Bali P; George P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Scuto A; Annavarapu S; Fiskus W; Moscinski L; Atadja P; Bhalla K
Clin Cancer Res; 2004 Aug; 10(15):4991-7. PubMed ID: 15297399
[TBL] [Abstract][Full Text] [Related]
14. Tet1 is not required for myeloid leukemogenesis by MLL-ENL in novel mouse models.
Ono R; Masuya M; Inoue N; Shinmei M; Ishii S; Maegawa Y; Maharjan BD; Katayama N; Nosaka T
PLoS One; 2021; 16(3):e0248425. PubMed ID: 33705482
[TBL] [Abstract][Full Text] [Related]
15. PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene.
Guo Z; Wang A; Zhang W; Levit M; Gao Q; Barberis C; Tabart M; Zhang J; Hoffmann D; Wiederschain D; Rocnik J; Sun F; Murtie J; Lengauer C; Gross S; Zhang B; Cheng H; Patel V; Schio L; Adrian F; Dorsch M; Garcia-Echeverria C; Huang SM
Blood; 2014 Sep; 124(11):1777-89. PubMed ID: 25006129
[TBL] [Abstract][Full Text] [Related]
16. PBX3 is an important cofactor of HOXA9 in leukemogenesis.
Li Z; Zhang Z; Li Y; Arnovitz S; Chen P; Huang H; Jiang X; Hong GM; Kunjamma RB; Ren H; He C; Wang CZ; Elkahloun AG; Valk PJ; Döhner K; Neilly MB; Bullinger L; Delwel R; Löwenberg B; Liu PP; Morgan R; Rowley JD; Yuan CS; Chen J
Blood; 2013 Feb; 121(8):1422-31. PubMed ID: 23264595
[TBL] [Abstract][Full Text] [Related]
17. Direct inhibition of dioxygenases TET1 by the rheumatoid arthritis drug auranofin selectively induces cancer cell death in T-ALL.
Chen L; Ren A; Zhao Y; Chen H; Wu Q; Zheng M; Zhang Z; Zhang T; Zhong W; Lin J; Zhu H
J Hematol Oncol; 2023 Nov; 16(1):113. PubMed ID: 37993905
[TBL] [Abstract][Full Text] [Related]
18. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
George P; Bali P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Fiskus W; Scuto A; Annavarapu S; Moscinski L; Bhalla K
Cancer Res; 2004 May; 64(10):3645-52. PubMed ID: 15150124
[TBL] [Abstract][Full Text] [Related]
19. A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells.
Gao XN; Lin J; Ning QY; Gao L; Yao YS; Zhou JH; Li YH; Wang LL; Yu L
PLoS One; 2013; 8(2):e55481. PubMed ID: 23390536
[TBL] [Abstract][Full Text] [Related]
20. Aberrantly low STAT3 and STAT5 responses are associated with poor outcome and an inflammatory gene expression signature in pediatric acute myeloid leukemia.
Narayanan P; Man TK; Gerbing RB; Ries R; Stevens AM; Wang YC; Long X; Gamis AS; Cooper T; Meshinchi S; Alonzo TA; Redell MS
Clin Transl Oncol; 2021 Oct; 23(10):2141-2154. PubMed ID: 33948920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
